-
Je něco špatně v tomto záznamu ?
Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε
A. Haag, V. Němec, P. Janovská, J. Bartošíková, B. Adhikari, J. Müller, MP. Schwalm, Š. Čada, U. Ohmayer, H. Daub, Y. Kim, F. Born, E. Wolf, V. Bryja, S. Knapp
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
European Research Council - International
- MeSH
- inhibitory proteinkinas * farmakologie chemie metabolismus MeSH
- kaseinkinasa Idelta * antagonisté a inhibitory metabolismus MeSH
- kaseinkinasa Iepsilon * antagonisté a inhibitory metabolismus MeSH
- lidé MeSH
- objevování léků MeSH
- proteolýza * účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Members of the casein kinase 1 (CK1) family have emerged as key regulators of cellular signaling and as potential drug targets. Functional annotation of the 7 human isoforms would benefit from isoform-selective inhibitors, allowing studies on the role of these enzymes in normal physiology and disease pathogenesis. However, due to significant sequence homology within the catalytic domain, isoform selectivity is difficult to achieve with conventional small molecules. Here, we used a PROTAC (Proteolysis TArgeting Chimeras) approach to develop a highly selective degrader AH078 (37) targeting CK1δ and CK1ε with excellent selectivity over the highly related CK1α isoform. The developed PROTAC, AH078 (37) selectively degraded CK1δ and CK1ε with a DC50 of 200 nM. Characterization of AH078 (37) revealed a VHL and Ubiquitin-dependent degradation mechanism. Thus, AH078 (37) represents a versatile chemical tool to study CK1δ and CK1ε function in cellular systems.
Department of Experimental Biology Faculty of Science Masaryk University 625 00 Brno Czech Republic
German translational cancer network site Frankfurt Mainz 60590 Heidelberg Germany
Institute of Biochemistry University of Kiel Rudolf Höber Str 1 Kiel 24118 Germany
NEOsphere Biotechnologies GmbH Fraunhoferstr 1 82152 Martinsried Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010301
- 003
- CZ-PrNML
- 005
- 20250429135047.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.4c02201 $2 doi
- 035 __
- $a (PubMed)39729064
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Haag, Adrian $u Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany $u Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany
- 245 10
- $a Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε / $c A. Haag, V. Němec, P. Janovská, J. Bartošíková, B. Adhikari, J. Müller, MP. Schwalm, Š. Čada, U. Ohmayer, H. Daub, Y. Kim, F. Born, E. Wolf, V. Bryja, S. Knapp
- 520 9_
- $a Members of the casein kinase 1 (CK1) family have emerged as key regulators of cellular signaling and as potential drug targets. Functional annotation of the 7 human isoforms would benefit from isoform-selective inhibitors, allowing studies on the role of these enzymes in normal physiology and disease pathogenesis. However, due to significant sequence homology within the catalytic domain, isoform selectivity is difficult to achieve with conventional small molecules. Here, we used a PROTAC (Proteolysis TArgeting Chimeras) approach to develop a highly selective degrader AH078 (37) targeting CK1δ and CK1ε with excellent selectivity over the highly related CK1α isoform. The developed PROTAC, AH078 (37) selectively degraded CK1δ and CK1ε with a DC50 of 200 nM. Characterization of AH078 (37) revealed a VHL and Ubiquitin-dependent degradation mechanism. Thus, AH078 (37) represents a versatile chemical tool to study CK1δ and CK1ε function in cellular systems.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kaseinkinasa Iepsilon $x antagonisté a inhibitory $x metabolismus $7 D048149
- 650 12
- $a kaseinkinasa Idelta $x antagonisté a inhibitory $x metabolismus $7 D048148
- 650 12
- $a proteolýza $x účinky léků $7 D059748
- 650 12
- $a inhibitory proteinkinas $x farmakologie $x chemie $x metabolismus $7 D047428
- 650 _2
- $a objevování léků $7 D055808
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Němec, Václav $u Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany $u Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany $1 https://orcid.org/0000000169001368
- 700 1_
- $a Janovská, Pavlína $u Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Bartošíková, Jana $u Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Adhikari, Bikash $u Institute of Biochemistry, University of Kiel, Rudolf-Höber-Str. 1, Kiel 24118, Germany
- 700 1_
- $a Müller, Juliane $u Institute of Biochemistry, University of Kiel, Rudolf-Höber-Str. 1, Kiel 24118, Germany
- 700 1_
- $a Schwalm, Martin P $u Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany $u Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany $1 https://orcid.org/0000000212521829
- 700 1_
- $a Čada, Štěpán $u Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Ohmayer, Uli $u NEOsphere Biotechnologies GmbH, Fraunhoferstr. 1, 82152 Martinsried, Germany
- 700 1_
- $a Daub, Henrik $u NEOsphere Biotechnologies GmbH, Fraunhoferstr. 1, 82152 Martinsried, Germany
- 700 1_
- $a Kim, Yeojin $u Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany $u Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany
- 700 1_
- $a Born, Florian $u Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany $u Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany
- 700 1_
- $a Wolf, Elmar $u Institute of Biochemistry, University of Kiel, Rudolf-Höber-Str. 1, Kiel 24118, Germany
- 700 1_
- $a Bryja, Vítězslav $u Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Knapp, Stefan $u Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany $u Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany $u German translational cancer network (DKTK) site Frankfurt Mainz, 60590 Heidelberg, Germany $1 https://orcid.org/0000000159956494
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 68, č. 1 (2025), s. 506-530
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39729064 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135042 $b ABA008
- 999 __
- $a ok $b bmc $g 2311577 $s 1247382
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 68 $c 1 $d 506-530 $e 20241227 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- GRA __
- $p European Research Council $2 International
- LZP __
- $a Pubmed-20250415
